Novo Nordisk A/S (NVO) Stock Analysis & Winston Score

Novo Nordisk is a Danish pharmaceutical company that makes medicines for people with diabetes and obesity. Its most well-known products are insulin treatments and the GLP-1 drugs Ozempic and Wegovy, which are used by millions of patients worldwide. It is one of the largest makers of diabetes medication in the world and supplies roughly half of the global insulin market. The company earns money by selling prescription drugs to patients through hospitals, pharmacies, and healthcare systems across more than 170 countries. Its strong patent protections, deep manufacturing expertise in biological drugs, and decades of brand trust in diabetes care give it a durable competitive position. The biggest growth driver is surging global demand for GLP-1 weight-loss and diabetes drugs, though the main risk is that patents will eventually expire and biosimilar competitors, along with potential drug pricing pressure from governments, could squeeze future revenues.